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Background: Tumor suppression of Transforming Growth Factor (TGF-β) signaling pathway requires an adaptor
protein, Embryonic Liver Fodrin (ELF). Disruption of ELF expression resulted in miscolocalization of Smad3 and
Smad4, then disruption of TGF-β signaling. However, the prognostic significance of ELF for hepatocellular carcinoma
(HCC) hasn’t been clarified. This study aimed to investigate whether measuring both TGF-β1 and ELF provides a
more powerful predictor for HCC prognosis than either marker alone.
Methods: TGF-β1 and ELF protein were detected by immunohistochemistry. The relationship between TGF-β1/ELF
expression and patients’ clinicopathologic factors was analyzed. The association between TGF-β1/ELF expression
and disease-free survival and overall survival was analyzed by Kaplan-Meier curves, the log-rank test, and Multivariate
Cox regression analyses.
Results: The expression of TGF-β1 in HCC tissues was significantly higher than that in normal liver tissues. Conversely,
the expression of ELF in HCC tissues declined markedly. ELF protein was correlated with HBsAg, tumor size, tumor
number, TNM and recurrence. Data also indicated a significant negative correlation between ELF and TGF-β1. Patients
with high TGF-β1 expression or/and low ELF expression appeared to have a poor postoperative disease-free survival
and overall survival compared with those with low TGF-β1 expression or/and high ELF expression. Furthermore, the
predictive range of ELF combined with TGF-β1 was more sensitive than that of either one alone.
Conclusions: TGF-β1 and ELF protein are potential and reliable biomarkers for predicting prognosis in HCC patients
after hepatic resection. Our current study has demonstrated that the prognostic accuracy of testing can be enhanced
by their combination.
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Hepatocellular cancer (HCC) is one of the most
common, aggressive malignancies, the third leading
cause of cancer-related deaths worldwide (World Health
Organization Report, 2006) [1-3]. Although surgical re-
section, percutaneous ablation and liver transplantation
are considered as the curative treatments for HCC, the
long-term prognosis of patients undergoing potentially
curative treatments is still poor. Fully 60% to 70% of pa-
tients develop recurrence or metastasis within 5 years
after resection [4,5]. It is therefore a very important and* Correspondence: hyp0427@163.com
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unless otherwise stated.urgent task to find an effective biomarker to identify pa-
tients with a high risk of recurrence or metastases, and
provide personalized therapy according to the predicted
risk of recurrence.
The transforming growth factor β (TGF-β) signaling
pathway is known to play an important role in multiple
cellular processes, including cell growth, differentiation,
adhesion, migration, apoptosis, extracellular matrix for-
mation and immunosuppressant [6-9]. TGF-β signals are
conveyed from type I and type II transmembrane serine/
threonine kinase receptors to the intracellular mediators-
Smad2 and Smad3, which further complex with Smad4,
translocate to the nucleus and bind to Smad-binding ele-
ments (SBE) in target gene promoters, thereby activating
its targets, such as p21, p15, p16, p27 [10-14]. TGF-β isis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hibiting cell cycle progression and arresting cells in early
G1 phase. However, misregulation of TGF-β signaling pro-
motes tumor growth and invasion, evasion of immune
surveillance, and cancer cell dissemination and metastasis
[11-14]. In HCC tissues, the overexpression of TGF-β1
was found and correlated with carcinogenesis, progres-
sion, and prognosis of HCC, while normal hepatocytes
had not any TGF-β1 staining [15]. In our previous study,
we found hepatocarcinogenesis could be closely related to
the low expression of Smad4 and phosphorylated Smad2,
and the high expression of TGF-β1 and Smad7 in ad-
vanced stage of liver cirrhosis [16].
Embryonic Liver Fodrin (ELF), also named as β2-
spectrin (β2SP), first isolated from foregut endodermal
stem cell libraries, functions as a Smad3/4 adaptor pro-
tein, plays critical roles in the proper control of Smad
access to activating receptors involved in regulation of
TGF-β signaling [17-19]. Interestingly, ELF is a key sup-
pressor of tumorigenesis [20,21]. Disruption of ELF ex-
pression by gene knockout was found to result in
miscolocalization of Smad3 and Smad4, and disruption
of TGF-β signaling [22]. About half of mice with hetero-
zygous deletion of ELF developed hepatocellular carcin-
oma, and 90% of ELF+/−/Smad4+/− mice developed gastric
cancer and other gastrointestinal cancers [23,24]. Loss of
ELF may play a role in the malignant transformation of
hepatic progenitor/stem cells [22]. However, the prognostic
value of ELF for HCC is not well-known. Testing the com-
bination of TGF-β1 and ELF as a predictor for HCC prog-
nosis is also merits study.
In the present study, we examined the pattern of ex-
pression of TGF-β1 and ELF in HCC tumor tissues and
normal tissues. Together with the known function, it is
therefore of interest to investigate that TGF-β1 and ELF
protein are potential and reliable biomarker for predict-
ing prognosis in HCC patients after hepatic resection,
and prognostic accuracy of testing can be enhanced by
their combination in the patients with HCC.
Methods
Patients and tissue samples
A total of 84 adult patients with HCC who underwent
hepatic resection in the Department of Hepatobiliary
Surgery, First Affiliated Hospital of Sun Yat-sen University
between June 2007 and October 2009, were enrolled
in this study, including 68 males and 16 females with
an average age of 48 years (range 23 to 75 years).
Written informed consent was obtained from all pa-
tients, and the study was conducted in accordance
with the protocol approved by the Declaration of Helsinki
and the guidelines of the Ethics Review Committee of First
Affiliated Hospital of Sun Yat-sen University. In addition,
normal liver tissues were collected from patients withcavernous hemangioma of liver or patients with intrahepa-
tic stones.
The diagnosis of HCC met the criteria of the American
Association for the study of Liver Disease [25]. The vol-
ume of liver resection and the surgical procedures were
decided by tumor size, tumor location, and liver functional
reserve based on a multidisciplinary team meeting every
week. Tumor stages were classified according to the
tumor-node-metastasis (TNM) system of the International
Union Against Cancer by the American Joint Committee
[26]. The histologic grade of tumor was assigned accord-
ing to the Edmondson Steiner grading system [27]. Fresh
HCC tissues and HCC adjacent tissues were collected
within 30 minutes after resection. These tissues were fixed
with 10% formalin and then embedded in paraffin.
Immunohistochemical analysis
The techniques have been described previously [16]. The
sections were incubated with pre-diluted primary Rabbit
polyclonal anti-ELF antibody (ab72239, Abcam, USA) at
a dilution of 1:100, with Rabbit monoclonal anti-TGF-β1
antibody (Y369, Bioworld, USA) at dilution of 1:100, at
4°C overnight. Negative controls were treated the same
way, omitting the primary antibodies.
Evaluation of immunohistochemical staining
The immunohistochemical staining in the tissue was
scored independently by 2 pathologists blinded to the
clinical data, by applying a semiquantitative immunore-
activity score (IRS) reported elsewhere [28-30]. Category A
documented the intensity of immunostaining as 0–3
(0, negative; 1, weak; 2, moderate; 3, strong). Category
B documented the percentage of immunoreactive cells
as 0 (less than 5%),1 (6%–25%), 2 (26%–50%), 3 (51%–
75%), and 4 (76%–100%). Multiplication of category A
and B resulted in an IRS ranging from 0 to 12 for each
tumor or nontumor. Sections with a total score of 0 or 1
or 2 were defined as negative (−), score of 3 or 4 were de-
fined as weakly positive (+), score of 6 or 8 were defined
as moderately positive (++), score of 9 or 12 were defined
as strongly positive (+++). For categorical analyses, the im-
munoreactivity was graded as low level (total score < =4)
or high level (total score >4).
Follow-up
The postoperative patients were followed up once a
month during the first half year post-operatively and
every 3 months thereafter. Serum AFP level and abdom-
inal ultrasonography were done routinely during the
postoperative review. Computed tomography (CT) was
performed every 3 to 6 months together with chest
radiographic examination. The endpoint of study was
December 2013. Survival time was calculated from
the date of surgery to the date of death or to the last
Table 1 The expression of ELF in HCC
Group n Expression of ELF
High Low
Normal liver tissues 20 20(100.0%) 0(0.0%)
Adjacent tissues* 84 65(77.4%) 19(22.6%)
HCC tissues*# 84 40(47.6%) 44(52.4%)
*compared with Normal liver tissues, P < 0.001 (by chi-square test).
#compared with Adjacent tissues, P < 0.001 (by chi-square test).
Table 2 The expression of TGF-β1 in HCC
Group n Expression of TGF-β1
High Low
Normal liver tissues 20 0(0.0%) 20(100.0%)
Adjacent tissues* 84 39(46.4%) 45(53.6%)
HCC tissues* 84 50(59.5%) 34(40.5%)
*compared with Normal liver tissues, P < 0.001 (by chi-square test).
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records or patients’ families through follow-up tele-
phone calls. Date of death for each case was double
verified by local civil affairs department and public
security department. The median follow-up period
was 39 months (range 3 to 81 months).
Recurrence or metastasis was detected by imaging
examination such as ultrasonography, contrast-enhanced
ultrasonography, CT, magnetic resonance imaging (MRI),
hepatic arterial angiography, or positron emission tomog-
raphy -CT (PET-CT). Isolated increases in serum AFP
were not regarded as recurrent events. Once tumor recur-
rence was verified, patients received the appropriate further
treatments, including repeat liver resection, radiofrequencyFigure 1 Expression of ELF and TGF-β1 protein. (A) Immunohistochemica
HCC adjacent tissues (Ab and Ae), HCC tissues (Ac and Af) (original magnificat
normal liver tissues (Normal), HCC adjacent tissues (Para-T) and HCC tissue (Tuablation, percutaneous ethanol injection, chemoemboliza-
tion, and/or molecular targeting therapy by sorafenib.
Statistical analysis
Statistical analyses were carried out using the SPSS v 13.
0 software (Chicago, IL, USA). The Wilcoxon W rank
sum test and chi-square test was used to compare
qualitative variables. Spearman correlation was used to
investigate the correlation between ELF and TGF-β1 ex-
pression. Survival curves were calculated using the
Kaplan-Meier method and were compared by a log-rank
test, illustrated by survival plots. The Cox proportional
hazards model was used to determine the independent
risk factors associated with prognosis. P < 0.05 was con-
sidered statistically significant.l staining in different tissues is shown. Normal liver tissues (Aa and Ad),
ion × 400). (B) and (C) Case distribution of ELF/TGF-β1 expression in
mor).
Table 3 Correlation between the clinicopathological characteristics and expression of ELF and TGF-β1 in the
84 HCC patients
Variables Cases ELF expression P value TGF-β1 expression P value
Low High Low High
Age(yrs)
> = 60 16 7(43.8%) 9(56.2%) 0.442 9(54.4%) 7(54.4%) 0.325
<60 68 37(54.4%) 31(45.6%) 29(42.6%) 39(57.4%)
Sex
Male 68 37(54.4%) 31(45.6%) 0.44 27(39.7%) 41(60.3%) 0.77
Female 16 7(43.8%) 9(56.2%) 7(43.8%) 9(56.2%)
HCC family history
Yes 6 2(33.3%) 4(66.7%) 0.83 3(50.0%) 3(50.0%) 0.95
No 78 42(53.8%) 36(46.2%) 31(39.7%) 47(60.3%)
HbsAg
Positive 72 41(56.9%) 31(43.1%) 0.04 29(40.3%) 43(59.7%) 0.93
Negative 12 3(25.0%) 9(75.0%) 5(41.7%) 7(58.3%)
ALT(U/L)
≥80 9 3(33.3%) 6(66.7%) 0.39 1(11.1%) 8(88.9%) 0.12
<80 75 41(54.7%) 34(45.3%) 33(44.0%) 42(56.0%)
PLT(×109)
>100 74 41(55.4%) 33(44.6%) 0.24 28(37.8%) 46(62.2%) 0.32
≤100 10 3(30.0%) 7(70.0%) 6(60.0%) 4(40.0%)
Cirrhosis
Yes 64 32(50.0%) 32(50.0%) 0.43 27(42.2%) 37(57.8%) 0.57
No 20 12(60.0%) 8(40.0%) 7(35.0%) 13(65.0%)
AFP(ug/L)
≥20 48 28(58.3%) 20(41.7%) 0.21 19(39.6%) 29(60.4%) 0.85
<20 36 16(44.4%) 20(55.6%) 15(41.7%) 21(58.3%)
Tumor size (cm)
≥5 50 32(64.0%) 18(36.0%) 0.01 13(26.0%) 37(74.0%) 0.001
<5 34 12(35.3%) 22(64.7%) 21(61.8%) 13(38.2%)
Tumor number
Single 62 26(41.9%) 36(58.1%) 0.001 31(50.0%) 31(50.0%) 0.003
Multiple 22 18(81.8%) 4(18.2%) 3(13.6%) 19(86.4%)
Differentiation
I-II 62 31(50.0%) 31(50.0%) 0.46 27(43.5%) 35(56.5%) 0.34
III-IV 22 13(59.1%) 9(40.9%) 7(31.8%) 15(68.2%)
TNM stage
I-II 55 24(43.6%) 31(56.4%) 0.03 29(52.7%) 26(47.3%) 0.002
III-IV 29 20(69.0%) 9(31.0%) 5(17.2%) 24(82.8%)
PVTT
Yes 11 8(72.7%) 3(27.3%) 0.15 2(18.2%) 9(81.8%) 0.11
No 73 36(49.3%) 37(50.7%) 32(43.8%) 41(56.2%)
Tumor encapsulation
Complete 64 30(46.9%) 34(53.1%) 0.07 29(45.3%) 35(54.7%) 0.11
None 20 14(70.0%) 6(30.0%) 5(25.0%) 15(75.0%)
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Table 3 Correlation between the clinicopathological characteristics and expression of ELF and TGF-β1 in the
84 HCC patients (Continued)
Recurrence
Yes 56 39(69.6%) 17(30.4%) <0.001 12(21.4%) 44(78.6%) <0.001
No 28 5(17.9%) 23(82.1%) 22(78.6%) 6(21.4%)
Complication
No 73 41(56.2%) 32(43.8%) 0.07 31(42.5%) 42(57.5%) 0.34
Yes 11 3(27.3%) 8(72.7%) 3(27.3%) 8(72.7%)
AFP, Alpha-fetoprotein; HBsAg, hepatitis B surface antigen; PLT, platelet; PVTT, portal vein tumor thrombi.
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The low expression of ELF and the high expression of
TGF-β1 in HCC tissues
Using immunohistochemical staining, we examine ex-
pression of ELF and TGF-β1 on 20 normal liver tissues,
84 HCC samples and adjacent tissues. All normal liver
tissues expressed high level of ELF (20/20). In HCC
adjacent tissues, there was a 77.4% high expression
rate for ELF (65/84). However, the ELF high expres-
sion rate declined to 47.6% (40/84) in HCC tissues.
There was significant difference among the groups ex-
amined (P < 0.001) (Table 1, Figure 1A, B). On the
contrary, the expression rate of TGF-β1 in HCC tis-
sues (59.5%, 50/84) was significantly higher than that
in the normal liver tissues (0, 0/20, P < 0.001), but not
in HCC adjacent tissues (46.4%, 39/84, P = 0.089,
Table 2, Figure 1A, C). These results suggested that
there was the low expression of ELF and high expres-
sion of TGF-β1 in HCC tissues.
Correlation between TGF-β1/ELF expression and 16
clinico-pathologic characteristics in HCC
In order to further understand the prognostic value of
TGF-β1/ELF expression for HCC after resection, the re-
lationships between the expression of these proteins and
16 clinico-pathologic characteristics, such as age, gender,
HCC family, HBsAg, ALT, AFP, cirrhosis, ascites, PVTT,
tumor size, tumor number, tumor differentiation, tumor
encapsulation, TNM stage, recurrence and complica-
tion, were analyzed. The expression level of ELF was
negatively correlated with HBsAg (P =0.04), tumor
size (P = 0.010), tumor number (P = 0.001), TNM stage
(P = 0.027) and recurrence (P < 0.001). As predicted,Table 4 The correlationship between ELF and TGF-β1
in HCC
ELF TGF-β1 r P value
+++ ++ - ~ +
+++ 7 4 12 −0.271 0.013
++ 4 1 12
- ~ + 20 14 10TGF-β1 expression was positively associated with the
tumor size (P = 0.001), tumor number (P = 0.003), TNM
stage (P = 0.002) and recurrence (P < 0.001), too (Table 3).
In addition, we found the significant negative correlation
between ELF and TGF-β1 expression patterns by using
Spearman correlation (r = −0.271, P = 0.013, Table 4).
Independent prognostic factors of HCC
To further identify the risk factors linked to postopera-
tive Disease Free Survival (DFS) and Overall Survival
(OS), ELF, TGF-β1 and 16 clinicopathologic factors were
evaluated by univariate analysis and the Cox regression
model. The univariate analysis showed that the signifi-
cant prognostic factors for DFS of HCC were tumor
number, portal vein tumor thrombus (PVTT), tumor en-
capsulation, TNM stage, ELF expression, and TGF-β1
expression. Similarly, the analysis showed that the sig-
nificant factors for OS of HCC were tumor number,
PVTT, tumor size, resection margin, tumor differenti-
ation, TNM stage, ELF expression, and TGF-β1 expres-
sion (all P < 0.05). Using the Cox regression multivariate
analysis, we found that PVTT, ELF expression, and
TGF-β1 expression were the significant independent re-
lated factors for DFS (all P < 0.05), in addition, tumor
differentiation (P = 0.029), PVTT (P = 0.011), ELF ex-
pression (P = 0.042) and TGF-β1 expression (P < 0.001)
were the significant independent related factors for OS
(Tables 5 and 6).
Low expression of ELF and high expression of TGF-β1
predict HCC patients’ poor prognosis
Firstly, we divided 84 patients with HCC into 2 groups
according to their ELF expression profiles: the low-
expression group (n = 44) and the high-expression group
(n = 40). Using the Kaplan-Meier method to analyze pa-
tients’ survival, we found that the 1-, 3- and 5-year DFS
rates of the high-expression ELF group were remarkably
higher than the low-expression group (75.0%, 60.0% and
57.5% vs 25.0%, 15.9% and 10.2%, respectively, P < 0.001)
(Figure 2A), while the 1-, 3- and 5-year OS rates of the
high-expression ELF group were significantly higher
than those of the low-expression group (90.0%, 72.5%
Table 5 Prognostic factors for DFS and OS by univariate analysis
Variables n DFS P OS P
1-yr 3-yrs 5-yrs 1-yr 3-yrs 5-yrs
Sex
Male 68 54.4% 36.8% 30.7% 0.53 79.4% 50.0% 41.2% 0.48
Female 16 56.3% 37.5% 37.5% 87.5% 56.3% 50.0%
Age(yrs)
<60 68 45.6% 32.4% 29.3% 0.15 82.4% 48.5% 39.7% 0.39
≥60 16 62.5% 56.3% 42.2% 75.0% 62.5% 56.3%
HCC family history
Yes 6 50.0% 33.3% 16.7% 0.57 83.3% 50.0% 50.0% 0.63
No 78 48.7% 37.2% 33.3% 79.5% 51.3% 42.3%
PLT(×109)
<100 10 80.0% 60.0% 60.0% 0.07 100.0% 80.0% 70.0% 0.08
≥100 74 44.6% 33.8% 28.2% 78.4% 47.3% 39.2%
HBsAg
Positive 72 47.2% 38.9% 33.3% 0.90 79.2% 50.0% 44.4% 0.88
Negative 12 58.3% 25.0% 25.0% 91.7% 58.3% 33.3%
AFP(μg/L)
<20 36 52.8% 38.9% 38.9% 0.34 83.3% 50.0% 44.4% 0.75
≥20 48 45.8% 35.4% 26.7% 79.2% 52.1% 41.7%
Ascites
No 68 52.9% 39.7% 34.1% 0.14 83.8% 51.5% 44.1% 0.55
Yes 16 31.3% 25.0% 25.0% 68.8% 50.0% 37.5%
Cirrhosis
No 24 45.0% 35.0% 30.0% 0.78 95.0% 60.0% 45.0% 0.49
Yes 60 50.0% 37.5% 32.9% 76.6% 48.4% 42.2%
Tumor number
Single 62 59.7% 43.5% 36.9% 0.003 85.5% 61.3% 51.6% <0.001
Multiple 22 18.2% 18.2% 18.2% 68.2% 22.7% 18.2%
PVTT
No 73 54.8% 41.1% 35.4% <0.001 87.7% 56.2% 47.9% <0.001
Yes 11 9.1% 9.1% 9.1% 36.4% 18.2% 9.1%
Tumor size (cm)
<5 34 64.7% 47.1% 39.2% 0.05 97.1% 67.6% 52.9% 0.04
≥5 50 38.0% 30.0% 28.0% 70.0% 40.0% 36.0%
Tumor encapsulation
None 20 30.0% 25.0% 15.0% 0.01 60.0% 45.0% 30.0% 0.08
Complete 64 54.7% 40.6% 37.7% 87.5% 53.1% 46.9%
Resection margin
<2 cm 45 40.0% 26.7% 24.4% 0.07 80.0% 40.0% 28.9% 0.01
≥2 cm 39 59.0% 48.7% 39.6% 82.1% 64.1% 59.0%
Complication
No 73 49.3% 38.4% 33.1% 0.37 84.9% 53.4% 45.2% 0.10
Yes 11 45.5% 27.3% 27.3% 54.5% 36.4% 27.3%
Tumor differetiation
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Table 5 Prognostic factors for DFS and OS by univariate analysis (Continued)
I-II 62 54.8% 41.9% 35.1% 0.16 85.5% 56.5% 48.4% 0.04
III-IV 22 31.8% 22.7% 22.7% 68.2% 36.4% 27.3%
TNM stage
I-II 55 60.0% 43.6% 38.0% 0.01 90.9% 60% 52.7% 0.001
III-IV 29 27.6% 24.1% 20.7% 62.1% 34.5% 24.1%
ELF expression
Low 44 25.0% 15.9% 10.2% <0.001 72.7% 31.8% 23.7% <0.001
High 40 75.0% 60.0% 57.5% 90.0% 72.5% 65.0%
TGFβ1 expression
Low 34 79.4% 73.5% 62.0% <0.001 94.1% 85.3% 76.5% <0.001
High 50 28.0% 12.0% 12.0% 72.0% 28.0% 20.0%
AFP, Alpha-fetoprotein; HBsAg, hepatitis B surface antigen; PLT, platelet; PVTT, portal vein tumor thrombi.
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P < 0.001) (Figure 2B). Our findings therefore indi-
cated that ELF expression levels were positively correlated
with patients’ DFS and OS.
Similarly, Two groups were divided from 84 HCC pa-
tients according to their TGF-β1 expression profiles: the
low-expression group (n = 34) and the high-expression
group (n = 50). We observed that the 1-, 3- and 5-year
DFS rates of the low-expression TGF-β1 group were
markedly higher than the high-expression group (79.4%,
73.5% and 62.0% vs 28.0%, 12.0% and 12.0%, respectively,
P < 0.001) (Figure 3A). Also, the 1-, 3- and 5-year OS
rates of the low-expression TGF-β1 group were signifi-
cantly higher than those of the high-expression group
(94.1%, 85.3% and 76.5% vs 72.0%, 28.0% and 20.0%, re-
spectively, P < 0.001) (Figure 3B). These data suggested
that TGF-β1 expression levels were negatively correlated
with patients’ DFS and OS.
The combination of TGF-β1 and ELF exhibits the
improved prognostic accuracy for HCC
To analyze the prognostic value of combining TGF-β1
and ELF levels for HCC, we divided patients into the fol-
lowing four groups, such as: TGF-β1 high expression-
ELF high expression group, TGF-β1 low expression- ELF






ELF expression 2.135 1.115-4.088
TGFβ1 expression 0.219 0.099-0.486
HR, hazard ratio; CI, confidence interval; PVTT, portal vein tumor thrombi.low expression group, TGF-β1 low expression- ELF low
expression group. The data showed that the TGF-β1 low
expression- ELF high expression group had the best DFS
and OS rates, TGF-β1 low expression- ELF low expres-
sion group was the second best, the next was TGF-β1
high expression- ELF high expression group, whereas
TGF-β1 high expression- ELF low expression group had
the worst prognosis.
The 1-, 3- and 5-year DFS rates of TGF-β1 low
expression- ELF high expression group (87.5%, 79.2%
and 75.0%) were significantly higher than those of
TGF-β1 high expression- ELF high expression group
(56.3%, 31.3% and 31.3%, P = 0.003) and TGF-β1 high
expression- ELF low expression group (26.5%, 2.9%
and 2.9%, P < 0.001). The 1-, 3- and 5-year OS rates of
TGF-β1 low expression- ELF high expression group
(95.8%, 91.7% and 83.3%) were also significantly higher
than those of TGF-β1 high expression- ELF high expres-
sion group (81.3%, 43.8% and 37.5%, P = 0.001) and TGF-
β1 high expression- ELF low expression group (67.6%,
20.6% and 11.8%, P < 0.001) (Figure 4A and B).
Furthermore, we found that the 1-, 3- and 5-year DFS
rates of TGF-β1 high expression-ELF low expression
(26.5%, 2.9% and 2.9%) were remarkably lower than TGF-
β1 high expression- ELF high expression (56.3%, 31.3%
and 31.3%, P = 0.002) and TGF-β1 low expression-ELFl by the multivariate Cox proportional hazards
OS
P HR 95% CI P
0.498 0.266-0.932 0.029
0.013 0.398 0.195-0.812 0.011
0.022 1.989 1.024-3.862 0.042
<0.001 0.210 0.093-0.474 <0.001
Figure 2 Kaplan-Meier curves are shown for time to disease recurrence (A) and overall survival (B) among patients with high or low
intratumoral ELF expression.
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the 1-, 3- and 5-year OS rates of TGF-β1 high expression-
ELF low expression (67.6%, 20.6% and 11.8%) were
markedly lower than TGF-β1 low expression-ELF low
expression group (90.0%, 70.0% and 60.0%, P = 0.003).
However, there was no significant difference of OS rates
between TGF-β1 high expression-ELF low expression
and TGF-β1 high expression- ELF high expression
(67.6%, 20.6% and 11.8% vs 81.3%, 43.8% and 37.5%,
respectively, P = 0.058). We also found no significant dif-
ference of DFS and OS rates between TGF-β1 low
expression-ELF high expression group and TGF-β1 low
expression- ELF low expression group, or between TGF-
β1 low expression-ELF low expression group and TGF-
β1 high expression-ELF high expression group (Figure 4A
and B). Collecting, the results indicated that the combin-
ation of TGF-β1 elevation and ELF reduction in HCC tis-
sues appears to be predictive of the poorest prognosis.Figure 3 Kaplan-Meier curves are shown for time to disease recurren
intratumoral TGF-β1 expression.Discussion
In the past few decades, great efforts have been made to
explore the molecular mechanism of HCC to identify
biomarkers for prediction and to develop effective treat-
ments. In this study, we focused on investigating the
prognostic significance of TGF-β1 and ELF, in particular
their combination, for HCC. Our first finding showed
that the TGF-β1 protein was upregulated in human
HCC tissues and no normal liver tissues with strong
cytoplasmic TGF-β1 protein immunostaining. The re-
sults were consistent with our previous study that the
low-expression of TGF-β1 in normal rat liver tissues and
the high-expression of TGF-β1 in rat HCC tissues [16].
Like others reports [31,32]. We also found the positive
correlation between TGF-β1 and several clinicopatho-
logical characteristics: tumor size, tumor number, TNM
stage and recurrence. A shorter post-operative survival
of HCC patients with high level of TGF-β1 had beence (A) and overall survival (B) among patients with high or low
Figure 4 The combination of ELF and TGF-β1 was found to enhance prognostic accuracy for HCC. Disease-free survival curves (A) and
overall survival curves (B).
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rates and OS rates of HCC patients with high level of
TGF-β1 were markedly lower than the low-expression
group.
Why do the functions of TGF-β switch from tumor
suppression to tumor promotion? Mishra L et al. indi-
cated that proper control of TGF-β signaling tumor sup-
pressor function requires an additional adaptor protein,
ELF. Research from that group indicated that disruption
of ELF expression results in miscolocalization of Smad3
and Smad4, then disruption of TGF-β signaling, allowing
normal cells to escape from the regulation of prolifera-
tion in carcinogenesis [21,33-36]. However, it was not
reported if ELF expression level correlated with survival
of HCC patients.
It is therefore of interest to investigate the expression
and clinical significance of ELF in patients with HCC.
We found that ELF was lost or underexpressed in the
majority of HCC tissues, and that a high level of ELF ex-
pression predicted a favorable DFS rate and OS rate for
HCC patients. Our data showed that the expression of
ELF negatively correlated with HbsAg, tumor size,
tumor number, TNM and recurrence. The 1-, 3- and 5-
year DFS rates of HCC patients with the high level of
ELF expression were remarkably higher than those of
HCC patinets with the low levels. Similarly, the 1-, 3-
and 5-year OS rates of HCC patients with the high level
of ELF expression were significantly higher than those of
HCC patients with the low levels. These data were con-
sistent with previous studies, which showed that signifi-
cant ELF reduction was found in HCC, gastric cancer
and lung cancer [33-36].
Further, we studied the correlation between ELF and
TGF-β1 in HCC patients, and demonstrated theirsignificant negative correlation. Then we used univariate
analysis and the Cox regression mode to study the role
of ELF and TGF-β1 on HCC, finding that the expression
of ELF and TGF-β1 were both significant and independ-
ent prognostic factors for DFS or OS of HCC. These
data further verified that ELF and TGF-β1 were import-
ant and promising candidate tumor biomarker for pre-
dicting the prognosis of patients with HCC, and we
hypothesized if combination of ELF and TGF-β1 could
give us a more sensitive way to predict HCC patients’
outcome.
It is widely understood that a combination of multiple
markers might yield more information for predicting
clinical outcome of HCC patients [37]. Elevation of
TGF-β1 or reduction of ELF in HCC tissues appears to
be predictive of a poor prognosis. The combination of
TGF-β1 and ELF expression were therefore used as a
predictor of clinical outcome. The results indicated that
their combination has a better prognostic value com-
pared with either one alone. For example, those patients
with low ELF expression and high TGF-β1 expression
had the poorest OS and DFS rates, whereas those pa-
tients with high ELF expression and low TGF-β1 expres-
sion had the most favorable OS and DFS rates. The
second best prognosis belonged to these patients with
low ELF expression and low TGF-β1 expression. In
addition, we found that high level of ELF could partially
rescue TGF-β1 related tumor promotion, but TGF-
β1still was the more important factor for prognosis of
patient with HCC.
Conclusions
Our study determined that loss or reduction of ELF
and elevation of TGF-β1 was correlated with disease
Ji et al. BMC Cancer  (2015) 15:116 Page 10 of 11progression and metastasis in patients with HCC. And
the most interesting finding was that the predictive range
of ELF levels combined with TGF-β1 expression was
more sensitive than that of either ELF or TGF-β1 alone
with regard to OS and cumulative disease recurrence in
patients with HCC. From a diagnostic viewpoint, our re-
sults suggest that the detection of tumor ELF alone or
the combined evaluation of ELF/ TGF-β1 levels could be
used as a new prognostic marker in patients with HCC.
However, the exact mechanisms of ELF and TGF-β1 ex-
pression regulation and function in HCC should been
elucidated further. In the future, ELF might be used as
potentially powerful target for treatment of HCC through
enhancing the tumor suppression of TGF-β pathway.
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